myeloid leukemia

(redirected from Myeloid leukaemia)
Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to Myeloid leukaemia: Chronic myeloid leukaemia

myeloid leukemia

Any of several forms of leukemia characterized by the proliferation of myeloid cells, especially granulocytes, and usually categorized into acute forms (acute myeloid leukemia) and chronic forms (chronic myelogenous leukemia). Also called granulocytic leukemia.

myeloid leukemia


1. pertaining to, derived from or resembling bone marrow.
2. pertaining to the spinal cord.
3. having the appearance of myelocytes, but not derived from bone marrow.

myeloid:erythroid (M:E) ratio
the ratio of myeloid to erythroid cells found in an examination of the bone marrow; provides an assessment of bone marrow activity.
myeloid leukemia
see myelocytic leukemia.
myeloid leukosis
myeloid metaplasia
hyperplasia of the bone marrow, with erythroid phthisis and compensatory splenomegaly and sometimes hepatomegaly. It is usually succeeded by bone marrow fibrosis and sclerosis. The initiating cause is usually not apparent.
myeloid tissue
red bone marrow.

Patient discussion about myeloid leukemia

Q. Are there any specific treatments for acute myeloid leukemia caused by myelofibrosis? My husband was diagnosed with these conditions. His oncologist believes his AML was caused by his myelofibrosis. (scarring of the bone marrow) This was shown on his bone marrow biopsy. Myelofibrosis is a myeloproliferative disorder. Meaning certain blood components, such as WBCs, RBCs, platelets increase significantly in the marrow.

A. Thanks for taking the time to reply to me. I'll see about inquiring his oncologists.

More discussions about myeloid leukemia
References in periodicals archive ?
Professor Mark Drakeford said: "I'm pleased to announce we will be making this medicine available to adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukaemia, following a recommendation from the All Wales Medicines Strategy Group.
Acute Myeloid Leukaemia Phase 3 Clinical Trial Pipeline Insights
Acute Myeloid Leukaemia Phase 2 Clinical Trial Pipeline Insights
Acute Myeloid Leukaemia Phase 1 Clinical Trial Pipeline Insights
Lead investigators presented the updated findings from the study involving more than 1,100 newly diagnosed patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) at the 50th Annual Meeting of the American Society of Haematology (ASH).
Chronic Myeloid Leukaemia Trialists' Collaborative Group.
Chronic myeloid leukaemia (CML) is an abnormality of white blood cell production.
Pat was first diagnosed in 1996 with chronic myeloid leukaemia and received a stem cell transplant three years ago.
Reflecting a greater understanding of disease biology, the enthusiastic pursuit of Flt-3 inhibition in the development of novel acute myeloid leukaemia treatment has resulted in already crowded pipeline, with four products challenging for first-to-market status: Cephalons CEP-701, Novartis PKC-412, Millenniums MLN518 and Pfizers SU11248.
Nasdaq:BIVN) today announced that the Scientific Program Committee of the American Society of Clinical Oncology (ASCO) has selected Bioenvision's Evoltra(TM) (clofarabine) adult acute myeloid leukaemia (AML) data for oral presentation at its 2006 ASCO Annual Meeting.
The filing was based on data from two pivotal Phase II trials in acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML) which will be presented at the 40th American Society of Clinical Oncology annual meeting in June.
Bioenvision is currently conducting further clinical studies with clofarabine throughout Europe, in refractory/relapsed paediatric acute leukaemia and in adult acute myeloid leukaemia.